Literature DB >> 20383296

HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis.

Willie Harrington1, Vincent Bond, Ming Bo Huang, Michael Powell, James Lillard, Upender Manne, Harvey Bumpers.   

Abstract

CXCR4 receptors have been implicated in tumorigenesis and proliferation, making it a potential target for colorectal cancer therapy. Expression of this chemokine receptor on cellular surfaces appears to promote metastasis by directly stimulating tumor cell migration and invasion. The receptor/ligand, CXCR4/SDF-1alpha, pair are critically important to angiogenesis and vascular remodeling which supports cancer proliferation. Our work has shown that a novel apoptotic peptide of HIV-1, Nef-M1, can act as a CXCR4 antagonist, inducing apoptosis in CXCR4 containing cells. Four colorectal tumor cell lines (HT-29, LS174t, SW480, WiDr), were evaluated for their response to Nef-M1 peptide via in vivo and in vitro. The presence of CXCR4 receptors on tumor cells was determined using immunohistochemical and RT-PCR analyses. Solid xenografts derived from tumor cell lines grown in SCID mice, were evaluated for the persistence of the receptor. Xenografts propagated in SCID mice from each of the four cell lines demonstrated high levels of receptor expression as well. The effects of Nef-M1 in vivo via splenic injected mice and subsequent hepatic metastasis also demonstrated dramatic reduction of primary tumor growth in the spleen and secondary invasion of the liver. We concluded that Nef-M1 peptide, through physical interaction(s) with CXCR4, drives apoptotic reduction in in vivo primary tumor growth and metastasis.

Entities:  

Year:  2009        PMID: 20383296      PMCID: PMC2851221          DOI: 10.4255/mcpharmacol.09.10

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  25 in total

Review 1.  Critical determinants of neoplastic angiogenesis.

Authors:  I J Fidler; R K Singh; J Yoneda; R Kumar; L Xu; Z Dong; D R Bielenberg; M McCarty; L M Ellis
Journal:  Cancer J       Date:  2000-05       Impact factor: 3.360

2.  Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 4.  Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer.

Authors:  M Z Dewan; S Ahmed; Y Iwasaki; K Ohba; M Toi; N Yamamoto
Journal:  Biomed Pharmacother       Date:  2006-06-28       Impact factor: 6.529

5.  Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice.

Authors:  H L Bumpers; T R Alosco; H Q Wang; N J Petrelli; E L Hoover; R B Bankert
Journal:  J Surg Res       Date:  1996-02-15       Impact factor: 2.192

6.  Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer.

Authors:  Harvey L Bumpers; Ming-Bo Huang; Michael Powell; William E Grizzle; James W Lillard; Joel Okoli; Vincent C Bond
Journal:  Cancer Biol Ther       Date:  2005-01-15       Impact factor: 4.742

7.  Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1.

Authors:  Ombretta Salvucci; Lei Yao; Sabrina Villalba; Agatha Sajewicz; Stefania Pittaluga; Giovanna Tosato
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

8.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

10.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.

Authors:  K Tachibana; S Hirota; H Iizasa; H Yoshida; K Kawabata; Y Kataoka; Y Kitamura; K Matsushima; N Yoshida; S Nishikawa; T Kishimoto; T Nagasawa
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  4 in total

1.  Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.

Authors:  Venkat R Katkoori; Marc D Basson; Vincent C Bond; Upender Manne; Harvey L Bumpers
Journal:  Oncotarget       Date:  2015-09-29

2.  Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells.

Authors:  Ming-Bo Huang; Ruben R Gonzalez; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2017-02-14

3.  Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells.

Authors:  Ming-Bo Huang; Kyle E Giesler; Brooke M Katzman; Anthony R Prosser; Valarie Truax; Dennis C Liotta; Lawrence J Wilson; Vincent C Bond
Journal:  Oncotarget       Date:  2018-02-26

4.  Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer.

Authors:  Harvey Bumpers; Ming-Bo Huang; Venkat Katkoori; Upender Manne; Vincent Bond
Journal:  J Cancer Ther       Date:  2013-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.